DiogenX logo

DiogenX

Targeting Beta Cell recovery in Diabetes

24 employees · est. 2020 · Marseille, France

VS
Kadimastem Ltd. logo

Kadimastem Ltd.

A clinical stage biotech company using PLATFORM TECH for the Manufacturing of cells for ALS and Diabetes treatments

32 employees · est. 2009 · Israel

Kadimastem Ltd. is the older company (2020 vs 2009).

Side-by-Side Comparison

DiogenX Kadimastem Ltd.
Founded
2020 2009 older
Headquarters
Marseille, France Israel
Employees
24 32
Industry
Not tracked yet Biotechnology, Health and Wellness
Funding Stage
Series A Grant
Total Funding
$38.00M $51.65M
Funding Rounds
4 8
Services
Discovery and Development of Biologics, Regenerative Treatment for Type 1 Diabetes Not tracked yet
Target Customers
Diabetic Patients, Healthcare Professionals, Research and Development Organizations Not tracked yet
Taxonomy
Biotech, Preclinical Stage, Beta-cell Recovery, Diabetes Therapeutics, Type 1 Diabetes, Type 2 Diabetes, Insulin-producing Cells, Pancreatic Beta-cell Modulators, Insulin Homeostasis, Novel Biologics, Collaborative Research, Clinical Innovation, Regenerative Medicine, Beta-cell Regeneration, Therapeutic Development Biotech, Stem Cell Therapy, Regenerative Medicine, Neurodegenerative Disorders, Cell Manufacturing, Drug Screening, High Content Screening, Cell-based Therapeutics, GMP Facilities, Type 1 Diabetes, ALS Treatment, Clinical Trials, Diabetes Cure, Israel, Bio-banking
Website
diogenx.com kadimastem.com
DiogenX logo

About DiogenX

DiogenX, founded in 2020, is a preclinical-stage biotech company based in France, with headquarters in Marseille and labs in Nice. The company operates under the slogan "Targeting Beta Cell recovery in Diabetes," reflecting its commitment to developing innovative biologics aimed at offering new ther...

Kadimastem Ltd. logo

About Kadimastem Ltd.

Kadimastem Ltd. is a clinical stage biotech company that has been disrupting the industry since its establishment in 2009. The company's slogan "A clinical stage biotech company using PLATFORM TECH for the Manufacturing of cells for ALS and Diabetes treatments" embodies its commitment to leveraging...

We will tell you when either one moves

BounceWatch watches DiogenX and Kadimastem Ltd. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at DiogenX and Kadimastem Ltd. — by email.

Frequently Asked Questions

DiogenX — Targeting Beta Cell recovery in Diabetes. Kadimastem Ltd. — A clinical stage biotech company using PLATFORM TECH for the Manufacturing of cells for ALS and Diabetes treatments. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
DiogenX has raised $38.00M while Kadimastem Ltd. has raised $51.65M.
DiogenX and Kadimastem Ltd. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare DiogenX with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at DiogenX on 11 May 2026, and Kadimastem Ltd. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy